Powered by

-Novartis builds on commitment to addressing need in neuropsychiatric disorders with Cadent Therapeutics acquisition

Dec 18, 2020 - ENP Newswire
Mergers and Acquisitions

Basel - Novartis has entered an agreement to acquire Cadent Therapeutics, a Cambridge, Massachusetts based neuroscience company.

The acquisition adds two new clinical stage programs to the Novartis neuroscience portfolio, one for schizophrenia and the other for movement disorders. The agreement also includes a buyout of milestones and royalties for MIJ821, a clinical stage molecule that Novartis licensed exclusively from Cadent in 2015. Novartis is actively developing MIJ821 for treatment ...